BOC, boceprevir; PR, peginterferon alfa-2b + ribavirin; SC, second cohort; VC, vanguard cohort.

*Patients receiving the 400 mg and 800 mg doses in the SC were down-dosed to receive 100 mg in an open-label fashion. Down dosing occurred in the SC at various time points while on MK-5172. No patients were dosed down in the VC.

Of those patients with bilirubin elevation, 92 percent (22/24) occurred within the first seven to 23 days of therapy, and their bilirubin levels decreased from peak levels despite continued dosing.

Patients With Late ALT/AST Elevations
                     
    Arm 1   Arm 2   Arm 3 (N=67)   Arm 4 (N=65)   Arm 5
Parameter   MK-5172   MK-5172   VC   SC*   VC   SC*   MK-5172
 

100 mg+ PR

200 mg+ PR
MK-5172 MK-5172 MK-5172 MK-5172
 

400 mg+ PR

400 mg+ PR

800 mg+ PR

800 mg+ PR

100 mg+ PR
 
    (n=66)   (n=68)   (n=24)   (n=43)   (n=29)   (n=36)   (n=66)

Patientswith LateALT/AST> 2x ULN
  1 (2%)   6 (9%)   5 (21%)   8 (19%)   7 (24%)   8 (22%)   1 (2%)
 

ALT, alanine aminotransferase; AST, aspartate aminotransferase; PR, peginterferon alfa-2b + ribavirin; ULN, upper limit of normal.

If you liked this article you might like

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

The 10 Stocks America's Biggest Hedge Funds Are Dumping Like Crazy

Why You Keep Cash on Hand; No Downside Conviction -- Jim Cramer's Top Thoughts